0000000000461065

AUTHOR

Catharina C. M. Beerendonk

showing 2 related works from this author

Effect of genetic variation in CYP450 on Gonadal impairment in a European cohort of female childhood cancer survivors, based on a candidate gene appr…

2021

Background: Female childhood cancer survivors (CCSs) carry a risk of therapy-related gonadal dysfunction. Alkylating agents (AA) are well-established risk factors, yet inter-individual variability in ovarian function is observed. Polymorphisms in CYP450 enzymes may explain this variability in AA-induced ovarian damage. We aimed to evaluate associations between previously identified genetic polymorphisms in CYP450 enzymes and AA-related ovarian function among adult CCSs. Methods: Anti-Müllerian hormone (AMH) levels served as a proxy for ovarian function in a discovery cohort of adult female CCSs, from the pan-European PanCareLIFE cohort (n = 743

OncologyInfertilityCancer ResearchCandidate genemedicine.medical_specialtyendocrine systemendocrine system diseasesMedizinAnti-Müllerian hormoneArticleHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Childhood cancer survivors03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-beingInterquartile rangeInternal medicineGenetic variationGenetic modelmedicineChemotherapyFertility preservationRC254-282030304 developmental biology0303 health sciencesbiologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensAnti-Müllerian hormonemedicine.diseaseOvarian functionCytochrome P450 genesWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthOncology030220 oncology & carcinogenesisCohortbiology.proteinCandidate gene approachbusinessGeneral Economics Econometrics and FinanceCancers
researchProduct

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

2020

Purpose Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale. Methods Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health–funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services. Results Sixty-three res…

Cancer Researchmedicine.medical_specialtyReferralmedia_common.quotation_subjectBest practiceMEDLINEFertilitylcsh:RC254-282Cost EffectivenessFertilidade03 medical and health sciences0302 clinical medicineSupportive Care and Quality of LifeJournal ArticleQuality of CareMedicineFertility preservationmedia_commonOncofertilityEthicsMedicine(all)Response rate (survey)030219 obstetrics & reproductive medicinebusiness.industryHealth Services and OutcomesORIGINAL REPORTSlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSupportive CarePolicy AnalysisWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthFertilityOncology030220 oncology & carcinogenesisFamily medicineScale (social sciences)Quality of Life/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428business
researchProduct